Kexing Biopharm is an innovative biopharmaceutical enterprise mainly engaged in the R&D, production and sales of recombinant protein therapeutics and microbiota agents. It focuses on pharmaceutical research in the therapeutic fields of antiviral, hematology, oncology and immunology, and degenerative diseases, and has accumulated know-how on traditional Chinese medicine and chemical pharmacy related technology in the above fields.
At present, our main products include the recombinant protein therapeutics "Recombinant Human Erythropoietin", "Recombinant Human Interferon α1b" and "Recombinant Human Granulocyte Colony-stimulating Factor", as well as the microbiota agents "Combined Clostridium Butyricum and Bifidobacterium".
Following the philosophy of "Precise Products, Predictable Effects, Health Protection", Kexing Biopharm Focus on the development strategy of biological drugs, and will continue to promote in research and development, industrialization, marketing, talent and organization, and ensure the implementation of the development strategy of biological drugs.
Chinese genetically engineered α1 interferon
Recombinant Human Interferon α1b for Injection (trade name: SINOGEN), included in the National Essential Medicines List and the National Reimbursement Drug List (category B), has broad-spectrum antiviral, antitumor, and immunoregulatory effects.
The Selection of Anti-anaemia in Multi-field
Recombinant Human Erythropoietin Injection (CHO cell) (trade name: EPOSINO), included in the National Essential Medicines List and the National Reimbursement Drug List (category B), covers the domestic clinical market in various provinces and has been exported to more than 20 countries including Brazil, Philippines, and Indonesia.
An initial choice for the prevention and treatment of neutrophilic granulocytopenia
Recombinant Human Granulocyte Colony-stimulating Factor Injection (rhG-CSF) (trade name: WHITE-C) is an initial choice for increasing leucocytes and improving the hematopoietic function of bone marrow after radiotherapy/chemotherapy.
A probiotic that is explicitly approved for use by the old and the young, as well as pregnant women before and after delivery, in the package insert.
Combined Clostridium Butyricum and Bifidobacterium Powder/Capsule, Live (CHANG LEKANG) is a combination of clostridium butyricunm and bifidobacterium infantis. Both bacterial strains are dominant in autochthonous intestinal flora and can synergistically promote the growth of each other. With proven immunoregulatory effect and a wide range of clinical applications and evidence-based support, it is a probiotic that is explicitly approved for use by the old and the young, as well as pregnant women before and after delivery, in the package insert.
?2017 Genzon Investment Group Co., Ltd. all rights reserved| 粵IPC備14060846號
